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A B S T R A C T   
Background: 20–60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic 
disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, 
radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global 
standard-of-care after nephrectomy remains active monitoring. Immune checkpoint inhibitors (ICIs) are effective 
in the treatment of metastatic RCC; RAMPART will investigate these agents in the adjuvant setting. 
Methods/design: RAMPART is an international, UK-led trial investigating the addition of ICIs after nephrectomy in 
patients with resected locally advanced RCC. RAMPART is a multi-arm multi-stage (MAMS) platform trial, upon 
which additional research questions may be addressed over time. The target population is patients with histo-
logically proven resected locally advanced RCC (clear cell and non-clear cell histological subtypes), with no 
residual macroscopic disease, who are at high or intermediate risk of relapse (Leibovich score 3–11). Patients 
with fully resected synchronous ipsilateral adrenal metastases are included. Participants are randomly assigned 
(3,2:2) to Arm A - active monitoring (no placebo) for one year, Arm B - durvalumab (PD-L1 inhibitor) 4-weekly 
for one year; or Arm C - combination therapy with durvalumab 4-weekly for one year plus two doses of trem-
elimumab (CTLA-4 inhibitor) at day 1 of the first two 4-weekly cycles. The co-primary outcomes are disease-free- 
survival (DFS) and overall survival (OS). Secondary outcomes include safety, metastasis-free survival, RCC 
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specific survival, quality of life, and patient and clinician preferences. Tumour tissue, plasma and urine are 
collected for molecular analysis (TransRAMPART). 
Trial registration: ISRCTN #: ISRCTN53348826, NCT #: NCT03288532, EUDRACT #: 2017–002329-39, CTA #: 
20363/0380/001–0001, MREC #: 17/LO/1875, ClinicalTrials.gov Identifier: NCT03288532, RAMPART grant 
number: MC_UU_12023/25, TransRAMPART grant number: A28690 Cancer Research UK, RAMPART Protocol 
version 5.0.   
1. Introduction 
Patients with intermediate or high-risk locally advanced renal cell 
cancer (RCC), as stratified by RCC specific prognostic scores, are at 
significant risk of relapse after surgical tumour resection. 20–30% of 
patients with intermediate risk and 40–60% of patients with high risk 
RCC develop metastatic disease following nephrectomy [1–3]. Between 
1 and 4% of patients with RCC present with synchronous ipsilateral 
adrenal metastases that can be resected at the time of nephrectomy [4]. 
These patients are treated adjuvantly, and they are considered to behave 
similarly to patients with high risk RCC. An effective strategy for 
reducing the risk of recurrence or death for patients with locally 
advanced, fully resected RCC remains an unmet clinical need. 
TKIs targeting the vascular endothelial growth-factor receptor are 
established in treating metastatic RCC and have been extensively tested 
in the adjuvant setting. Five TKI trials have produced results: ASSURE, 
PROTECT, S-TRAC, ATLAS and now SORCE [5–10]. These studies 
evaluated the effect of oral TKIs compared to placebo and none have 
shown a benefit of TKI on overall survival (OS) [10,11]. Only the S- 
TRAC trial showed a modest DFS benefit with 1 year of sunitinib (HR 
0.76; 95% CI 0.59–0.98; p = 0.03) compared to placebo on blinded in-
dependent central review [7]. 63% of sunitinib treated patients expe-
rienced Grade ≥ 3 toxicities, with many patients unwilling or unable to 
complete treatment. On this basis, the Food and Drug Administration 
(FDA) approved sunitinib for the adjuvant treatment of patients with 
high risk RCC. However, given the toxicity and cost associated with 
sunitinib in this setting, the results have not been universally practice 
changing. Therefore, nephrectomy followed by active surveillance for 
relapse, remains the predominant standard of care globally. 
Treatment with ICIs, either as a dual combination or in combination 
with TKIs have revolutionised the management of patients with 
advanced RCC. The combination of ipilimumab, a monoclonal antibody 
against human cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) 
with nivolumab, a monoclonal antibody against programmed cell death 
protein-1(PD-1) is now a first line treatment for patients with interme-
diate or poor risk advanced RCC, classified according to the Interna-
tional Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) 
model [12]). This followed findings from CHECKMATE-214 [13], a 
phase III study showing an 18 month OS of 75% (95% CI; 70–78) for the 
combination ICI group versus 60% (95% CI; 55–65) for sunitinib [14]. In 
addition, single agent nivolumab, is routinely available in the second 
line setting for patients who have progressed on TKI therapy regardless 
of IMDC risk, based on a 5.6 month OS benefit of nivolumab over 
everolimus [15]. There are now a number of ICI and TKI combination 
strategies which have shown efficacy benefit over sunitinib in the first 
line setting, including axitinib (TKI) with avelumab (anti-programmed 
death-ligand 1 (PD-L1)), axitinib with pembrolizumab (anti-PD-1), 
pembrolizumab with lenvatinib (TKI) and nivolumab with cabozantinib 
(TKI) [16–19]. 
Durvalumab (anti PD-L1) and tremelimumab (anti-CTLA-4) are 
agents of the same class as other ICIs. Durvalumab is efficacious for 
patients with non-small-cell lung cancer who have completed definitive 
chemo-radiotherapy, showning a progression free survival (PFS) 
advantage of 11.2 months in patients receiving durvalumab compared 
with placebo [20]. Durvalumab in combination with tremelimumab has 
shown benefit to OS and PFS in the third-line treatment of patients with 
metastatic NSCLC, (in those with PD-L1 tumour cells ≥25%) and is being 
evaluated in the advanced setting in patients with various tumour types 
(NCT03298451), (NCT03994393) and (NCT02516241). 
Therefore, the RAMPART trial, led by the MRC CTU at University 
College London (UCL) and working in partnership with AstraZeneca, is 
investigating the activity of durvalumab alone and in combination with 
tremelimumab after nephrectomy for patients with locally advanced 
RCC. There is also potential for adding additional research arms as the 
trial progresses. 
2. Methods 
2.1. Overview of design 
RAMPART is a phase III, multi-arm multi-stage (MAMS) trial, initi-
ated with a control (Arm A; active monitoring) and two research arms, 
(Arm B; durvalumab and Arm C; durvaumab with tremilimumab) 
(Fig. 1). Initially, participants with Leibovich scores 3 to 11 (interme-
diate and high risk) [21] are eligible to be randomised. Intermediate-risk 
participants (Leibovich scores 3–5) will be capped at 25% of the total 
accrual target or after four years of recruitment, whichever is earlier. 
Inclusion of intermediate risk participants acknowledges that they are at 
a substantial risk of relapse, although they tend to occur later than those 
at high risk. By including the intermediate-risk participants during the 
early years of the trial, there will be sufficient numbers, followed for 
long enough, to contribute to the disease-free survival (DFS) analysis. 
Recruitment of participants with Leibovich scores 6 to 11 will continue 
to the accrual target of 1750 participants. Participants with ipsilateral 
adrenal metastases that are completely resected at the time of ne-
phrectomy are eligible for RAMPART, which was a mid-trial protocol 
change implemented in July 2021. 
2.2. Outcome measures 
There are two co-primary endpoints in RAMPART, DFS and OS. DFS 
is defined as the interval from randomisation to first evidence of local 
recurrence, new primary renal cell carcinoma (RCC), distant metastases, 
or death from any cause, whichever occurs first. OS is defined as all- 
cause mortality; the time from randomisation to death from any cause. 
An adjuvant trial focusing on DFS and OS independently would take up 
to fifteen to twenty years to report its results and would potentially deny 
many thousands of patients the opportunity to benefit from promising 
new treatments. Therefore, both DFS and OS were accepted, after reg-
ulatory and scientific review, as co-primary endpoints. OS will be 
examined conditional on seeing improvements in DFS. However, DFS is 
the primary outcome on which regulatory approval will be sought for 
durvalumab monotherapy and/or the combination of durvalumab and 
tremelimumab. Reporting both DFS and OS as co-primary endpoints will 
provide the complete picture and allow clinicians and regulators to 
make fully informed treatment decisions. 
The following secondary outcome measures will be analysed:  
• Safety 
• Metastasis-free survival (MFS), defined as the interval from ran-
domisation to first evidence of metastases or death from RCC;  
• RCC specific survival time, defined as the time from randomisation to 
death from RCC;  
• Quality of Life (EQ-5D, EORTC QLQ-C30) 
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• Preferences for Adjuvant Immunotherapy in RAMPART (PAIR) sub- 
study questionnaire at baseline, week 16 and after completing 
treatment at month 15. 
2.3. Sample size 
RAMPART is powered for both the DFS and OS outcomes. The sample 
size calculations and design characteristics for RAMPART were obtained 
using nstage (version 3.0.1, 10-Sep-2014). Specifically, the nstage pro-
gram was used to obtain the ‘ideal’ target number of control arm events 
needed at each stage for each comparison and an approximate idea for 
the timing of the stages. Artpep (version 1.0.4 PR 05-Jul-2013) was then 
used to project a more realistic analysis timeline using accrual and time- 
to-event patterns based on the SORCE trial (ISRCTN: ISRCTN38934710, 
EUDRACT: 2006–006079-19; NCT00492258). ART (version 1.1.0, 10- 
Dec-2013) was used to determine the absolute differences in DFS and 
OS at relevant time points. All calculations were performed in Stata 
14.1. 
Using control arm data from the SORCE trial [9] we anticipate a 3- 
year DFS rate of 65% for the control arm of RAMPART. We plan to re-
cruit 1750 participants (750 to Arm A, 500 to Arm B and 500 to Arm C) 
over approximately 5.5 years but will continue until the accrual target is 
reached. 
2.4. Adjusting sample size estimates for multiple comparisons 
We have adjusted the RAMPART sample size to allow for multiple 
comparisons. The overall type I error rate – i.e. the family-wise type I 
error rate (FWER) [19] - is strongly controlled at 2.5% for all the pair-
wise comparisons whether or not a new research arm is added. Simu-
lations were used to find the final stage significance level that control the 
FWER across the three pairwise comparisons. We considered two 
different scenarios: 1) the trial starts (and possibly concludes) with two 
research arms B and C, 2) or a new research arm (Arm D) is added before 
accrual to the current 3-arm trial completes. We applied Dunnett’s 
approach to calculate the FWER in both scenarios 1 and 2. The results 
showed that the final stage significance level of 0.0097 in all pairwise 
comparisons controls the overall FWER at 2.5% when Arm D is added 
later on. Our simulations also showed that the final stage significance 
level of the two original pairwise comparisons can be increased to 0.015 
if the deferred arm is not added, to buy back the unspent type I error of 
the third pairwise comparison. The relevant methods to calculate the 
correlation structure are described in Choodari-Oskooei et al. (2020) 
[22]. 
2.5. Eligibility and participant recruitment 
Participants entering the RAMPART trial have undergone potentially 
curative nephrectomy for RCC and must satisfy the eligibility criteria, 
summarised in Tables 1 and 2. The time window for entry (up to 12 
weeks post nephrectomy) allows treatment to be started at the earliest 
opportunity to maximise the potential benefits, whilst also considering 
safety from a post-surgical perspective. 
2.6. Site recruitment 
RAMPART is open to hospitals throughout the United Kingdom (UK). 
Recruitment will commence in Australia, New Zealand, France and 
Spain in mid 2021 (other countries may join subsequently). 
UK site recruitment has been organised in ‘waves’ of hospitals, 
grouped by geography and also by their accrual to SORCE. Doing this 
has enabled more individualised site support. Lessons learnt from 
opening successive waves helps with optimising and refining activation 
processes, training of hospital staff and the provision of more useful 
guidance documents. Given the novel nature of the treatments and 
concerns around potential toxicity, the trial management team have 
been able to keep a closer eye on safety with a smaller initial group of 
sites. 
2.7. RAMPART and the COVID-19 pandemic 
Recruitment of participants into RAMPART and the treatment of 
existing RAMPART participants was suspended on 23-Mar-2020 due to 
the COVID-19 pandemic as it was unknown whether durvalumab and/or 
tremelimumab would lead to an increased risk or severity of COVID-19 
for RAMPART participants. AstraZeneca subsequently advised that there 
Paents with fully resected RCC (+/-synchronous adrenal metastases removed at me of 
nephrectomy*) 
Intermediate or high Leibovich score
Randomisaon (within 12 weeks of surgery)








75mg at day 1 and 
week 4
Arm D
to be added at a 








Fig. 1. Trial schema.  
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was no evidence linking participants treated with either drug or the 
combination to a higher risk or severity of COVID-19 infection. As the 
potential benefits of treatment in the RAMPART trial outweigh the risks 
overall, RAMPART was re-opened on 07-Jul-2020. Sites were advised to 
restart treatment of existing participants and recruit new participants as 
and when they could. 
Significant changes have been made to the RAMPART protocol 
during the pandemic to optimise safety for participants in terms of 
minimising time spent in hospital. Sites are now permitted to complete 
the participant consent process via either video or phone, where it forms 
part of local policy to reduce patient exposure to COVID-19. For more 
details on the Remote Consent Policy see RAMPART protocol version 5.0 
[23]. In addition, the COVID-19 pandemic has significantly impacted 
the way in which clinical assessments can be conducted by sites and is 
highlighted below. These changes have enabled the RAMPART trial to 
remain active through subsequent waves of the pandemic. 
2.8. Randomisation 
Participants are randomised centrally between Arm A and the 
research Arms B and C using stratified block randomisation in the ratio 
3:2:2. Treatment allocation is not blinded. To decrease determinability, 
the stratification factors are not listed here but are described in the 
RAMPART Statistical Analysis Plan, which will be finalized and 
published prior to the first interim analysis. Participants randomised to 
Arms B and C start treatment within 14 days of randomisation. 
2.9. Treatment schedule and assessments 
Participants in Arm B receive a fixed dose of 1500 mg durvalumab 
via IV infusion every four weeks for up to 13 cycles. Participants in Arm 
C receive four weekly 1500 mg durvalumab IV for a total of 13 cycles 
and two doses of 75 mg tremelimumab IV with the first and second 
cycles of durvalumab. 
Participants in the active monitoring arm (Arm A) receive no drug; 
however they are radiologically assessed at the same frequency as par-
ticipants on the active treatment arms. Arm A participants are clinically 
assessed at weeks 16, 32 and 52. Participants in arms B and C are 
assessed at day 1, then on a 2 weekly basis until week 8, and then every 
4 weeks until week 52. 
Since the COVID-19 pandemic there is now a greater emphasis on 
remote clinical assessments and this approach is supported by patient 
groups. Therefore, where it is deemed appropriate by the investigator, 
the pre-treatment clinical assessments can be carried out remotely (via 
telephone or video). The laboratory tests may be completed at the par-
ticipants GP or a local hospital. Once the assessments have been 
completed at week 52 all participants will move into follow-up phase. 
Table 1 
Inclusion criteria (see protocol for more detailed list). 
WHO World Health Organisation; PS Performance status; FFPE Formalin-fixed paraffin embedded; AST aspartate aminotransferase; ALT alanine 
aminotransferase; ULN upper limit normal. 
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2.10. Criteria for discontinuing allocated interventions 
An individual participant may stop treatment early for any of the 
following reasons.  
• Disease progression  
• Unacceptable toxicity, Inter-current illness or change in patient’s 
condition that justifies discontinuation  
• Any change in the patient’s condition that in the clinician’s opinion 
makes continuing investigational medicinal product a safety risk.  
• Pregnancy or intent to become pregnant  
• Grade ≥ 3 infusion reaction  
• Initiation of alternative anticancer therapy including another 
investigational agent  
• Withdrawal of consent for treatment by the patient  
• Missing consecutive treatment visits1. 
Table 2 
Exclusion criteria. 
CTCAE Common Terminology Criteria for Adverse Events; RCT randomised controlled trial, FFPE Formalin-fixed paraffin embedded; CPDA 
citrate-phosphate-dextrose solution with adenine. 
1 For treatment breaks due to COVID-19 infection, there is no specified 
maximum time between durvalumab infusions prior to restarting treatment. 
The second dose of tremelimumab for Arm C participants however, must be 
given within 12 weeks of starting trial treatment. Regardless of any adminis-
tration delays, the maximum duration of durvalumab treatment must not 
exceed 1 year. 
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2.11. Participant follow-up 
Participants on all arms who have not progressed are seen at week 52 
(end of year one), and are followed-up on a three monthly basis until the 
end of year three. Initially, they have CT scans (with contrast) of the 
chest, abdomen and pelvis every six months. After year three, partici-
pants have annual clinical follow-up with a CT until year five. For the 
purposes of the trial, participants have a CT scan at either years seven or 
eight and a further CT scan at ten years. Follow-up assessments may be 
conducted in person or remotely (via telephone or video) if deemed 
appropriate. The trial follow-up schedule is described in Table 3. 
2.12. Tumour assessment 
The DFS outcome will be investigator-reported and must be based on 
thorough investigation and evidence such unequivocal radiological 
progression or biopsy. Site specific combined imaging and surgical re-
view, followed by histopathological discussion (if relevant) at multi- 
disciplinary team discussion is the routine way in which DFS events 
are classified. 
2.13. Safety/toxicity management 
ICIs aim to boost endogenous immune responses directed against 
tumour cells. This augmented immune response may lead to activation 
of autoreactive T-cells that damage host tissues. Immune-related adverse 
events (ir-AEs) can affect any body system. Combined PDL-1 plus CTLA- 
4 blockade is likely to trigger more ir-AEs than anti PD-1 alone. A 
comprehensive toxicity management guide is provided to all in-
vestigators to manage potential ir-AEs based on the severity of 
treatment-emergent toxicities graded per NCI CTCAE v4.03 [23]. It in-
cludes criteria for permanent discontinuation of study drug/study 
regimen based on CTCAE grade. In addition, study drug should be 
permanently discontinue for the following conditions:  
• If an ir-AE results in missing consecutive treatment visits. Inability to 
reduce corticosteroid to a dose of ≤10 mg of prednisone per day (or 
equivalent) within 8 weeks after last dose of study drug/study 
regimen  
• Grade ≥ 3 recurrence of an ir-AE following resumption of dosing  
• Grade ≥ 3 infusion reaction 
2.14. Monitoring 
The monitoring plan for RAMPART is based on a formal risk 
assessment, initially undertaken during trial development. The plan is 
reviewed and updated as appropriate on at least an annual basis. 
The RAMPART team conduct central and on-site monitoring checks 
to identify potential issues with consent, eligibility, treatment admin-
istration, drug supply and safety monitoring. Any issues identified will 
be raised and discussed with the local team. 
Each participating site will have their first on-site monitoring visit 
within one year of randomising a patient to active treatment, (Arms B or 
C). The frequency of subsequent visits to sites will be determined by the 
outcomes of central monitoring. At times when site visits are difficult to 
conduct (e.g. COVID-19 pandemic), more central monitoring checks are 
performed to check site compliance. 
2.15. Data management 
Paper CRFs are used in RAMPART. Original copies of CRFs are 
retained at individual sites whilst copies are sent via secure email to the 
MRC CTU at UCL where they are stored securely. Key variable checks are 
performed on receipt of all RAMPART CRFs to ensure any potential 
safety issues are rapidly identified. Data is single entered onto a cus-
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in validations (value ranges, date inconstancies, treatment administra-
tion) to help ensure the data is both accurate and correct. The RAMPART 
Data Management Plan provides a comprehensive breakdown of how 
data is to be acquired, handled and secured. 
2.16. Statistical analysis plan 
All efficacy analyses will be performed in the intention-to-treat 
population. The treatment effect for each of the initial two treatment 
comparisons and each of the two co-primary outcomes will be assessed 
using a stratified Cox model, stratifying for the factors used in ran-
domisation. Data will be presented graphically using Kaplan-Meier 
plots. The Chi-squared test or Mann-Whitney test will be implemented 
for categorical data comparisons, including toxicity, as appropriate. 
Subgroup analyses will be conducted to assess consistency of treatment 
effect across potential or expected prognostic factors, including sub-
group analyses by PD-L1 baseline expression status. Full details of all 
planned analyses are documented in the RAMPART Statistical Analysis 
Plan. 
2.17. Interim analyses for disease-free survival (DFS) 
As part of the MAMS design, one interim analysis is planned for the 
comparison of Arm C vs Arm A (combination vs control) and three 
interim analyses are planned for the comparison of Arm B vs Arm A 
(monotherapy vs control). Each one will consider both a lack-of-benefit 
and overwhelming benefit of treatment on DFS. Both sets of stopping 
boundaries are included in the RAMPART protocol [23]. 
Based on assumptions for accrual and survival distribution for the 
control arm, at the time of the trial design the first interim analyses were 
planned 4.75 years after the trial started. However, the exact timing of 
the interim analyses will be subject to change as they are time-to-event 
analyses. The most up-to-date information on the timeline for interim 
analyses can be found in the RAMPART protocol [23]. 
2.18. Primary DFS analysis 
The primary DFS analysis of Arm C vs Arm A is planned when 276 
control arm event events have been observed, The target HR for Arm C 
versus Arm A is 0.70, which translates to an absolute improvement in 3- 
year DFS of 9%, from 65% to 74%. This design gives 87.3% power to 
detect this difference at the 0.0097 one-sided significance level. If the 
DFS result at this time point is positive, OS will also be analysed using a 
closed test, even though the data will be not be fully mature, allowing for 
a more complete assessment of the DFS results. 
2.19. Overall survival 
The primary OS analysis is planned in high risk participants only 
(with Leibovich Score 6–11). With approximately 940 high-risk partic-
ipants in the Arm C vs Arm A comparison, we will have 80% power to 
detect a HR of 0.7. This HR translates to an absolute difference in OS at 5 
years of 6.5%, increasing survival from 76% to 82.5%. 
With approximately 940 high-risk participants in the Arm B vs Arm A 
comparison, we will have 80% power to detect a HR of 0.75. This HR 
translates to an absolute difference in OS at 5 years of 5.4%, increasing 
survival from 76% to 81.4%. 
2.20. Translational studies/sub-studies 
2.20.1. TransRAMPART 
TransRAMPART is the Cancer Research UK (CRUK) funded trans-
lational study linked to RAMPART. TransRAMPART is an expanded 
sample collection, building on the samples already obtained through 
RAMPART and supplementing them with additional sample types and 
collection time points. To ensure that all sites can contribute to the 
study, we have defined three participation levels (Bronze, Silver and 
Gold). For more details see TransRAMPART protocol [24] and the 
sample collection manual [25]. 
2.21. Safety and efficacy of the COVID-19 vaccines 
There is little published prospective data on the safety of COVID-19 
vaccines for participants receiving ICI therapy. In RAMPART we will be 
publishing the vaccinations our participants receive, any adverse events 
that they experience following administration of the vaccine as well as 
any subsequent COVID-19 infections. Relevant information for trial 
participants should be submitted on the COVID-19 case report form 
(CRF). 
2.22. Regulatory and ethical considerations 
The trial will be conducted in compliance with the approved protocol 
of the Declaration of Helsinki 2008, the principles of Good Clinical 
Practice (GCP), Commission Directive 2005/28/EC with implementa-
tion in national legislation in the UK by Statutory Instrument 2004/1031 
and subsequent amendments, the EU General Data Protection Regula-
tion (GDPR), and the National Health Service (NHS) Research Gover-
nance Framework for Health and Social Care (RGF). International 
centres will comply with the principles of GCP as laid down by the ICH 
topic E6 R2 (Note for Guidance on GCP) and applicable national 
regulations. 
Scientific advice on the clinical trial protocol has been obtained from 
both the European Medicines 
Agency (EMA) and FDA. Sufficient elements are in place to enable 
compliance with ICH GCP (both retrospectively and prospectively) if it is 
decided at a later stage that trial data are to be submitted to regulatory 
authorities as part of a licensing application. 
The Medicines and Healthcare Products Regulatory Agency (MHRA) 
granted the Clinical Trials Authorisation on the 24th November 2018. 
The London Riverside Research Ethics Committee granted ethical 
approval on 8th January 2018. 
2.23. Patient and public involvement 
The RAMPART Trial Management Group (TMG) is committed to 
engaging with the public and involving patient representatives in all 
aspects of the trial. Patient Public Involvement (PPI) activities include 
commenting on grant applications, promotion of the trial at start-up, 
advising on strategies to aid patient recruitment and ongoing engage-
ment with relevant patient groups and charities. Patient newsletters, 
information sheets and trial promotional videos have been developed by 
the trial management team with the support of PPI delegates. 
Patient representatives are members of the RAMPART TMG while 
other patient representatives are members of the MRC CTU Genitouri-
nary Trial Steering Committee (TSC) and therefore are actively involved 
in discussions on trial progress including IDMC recommendations. 
2.24. Trial oversight 
RAMPART is sponsored by UCL. The MRC CTU at UCL has overall 
responsibility for the study working closely with the Chief Investigator, 
all members of the TMG and all collaborators. The Trial Management 
Team (TMT) meet on a weekly basis to discuss all aspects of trial 
conduct, including for example site set-up, participant accrual and safety 
management. The TMT report to the TMG. The TMG is responsible for 
the running of the trial and meets at least six times a year. An Inde-
pendent Data Monitoring Committee (IDMC) meet approximately 
annually to review safety, compliance with treatment and efficacy data 
(at pre-planned interim analyses). They are the only group who see the 
confidential, accumulating efficacy data for the trial. The IDMC advise 
the TSC. The TSC provides overall supervision of the trial and provides 
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advice and recommendations through its independent Chair. The ulti-
mate decision for the continuation of the trial lies with the TSC. 
2.25. Use of electronic health records (EHR) 
We plan to incorporate the use of EHR to improve on follow-up of 
participants enrolled to RAMPART by charting their health status and 
survival, for example, from records maintained by NHS Central Registry 
or any applicable national registry. 
3. Conclusion 
RAMPART is an international, UK-led trial that will assess the benefit 
of ICIs in participants at intermediate and high risk of recurrence after 
surgical resection of locally advanced RCC. Participants with synchro-
nous ipsilateral adrenal metastases, removed at the time of nephrectomy 
are included in RAMPART (implemented in July 2021). 
The first patient was randomely assigned in October 2018. By the end 
of June 2021, 259 of the target of 1750 participants from 34 UK sites 
were recruited. Recruitment of intermediate risk participants continues, 
(25% cap has not been reached). After a short pause at the start of the 
COVID-19 pandemic, RAMPART has re-established recruitment in the 
UK and in mid 2021 opened in France, Australia and Spain. There have 
been no safety concerns highlighted in IDMC safety reviews to date. 
RAMPART is a three arm adaptive MAMS platform trial upon which 
at least one new research arm (Arm D) can be added over the coming 
years. Importantly, the RAMPART trial design allows the control arm to 
be amended should the standard of care change. This will allow progress 
to be made in the treatment of locally advanced RCC within the 
framework of one trial rather than starting a competing trial or waiting a 
number of years, until the first trial reports. This is critical in the adju-
vant setting in RCC where it takes international collaborations many 
years to develop, launch and deliver a trial. ‘RAMPART: A Model for a 
regulatory ready academic led phase III trial in the adjuvant RCC setting’ 
(Contemporary Clinical Trials [26]), outlines the pertinent lessons we 
have learnt during the process of trial design, development and conduct. 
TransRAMPART is a unique scientific collaboration that will provide 
an opportunity to address unanswered issues for patients with locally 
advanced RCC including which patients are most in need of adjuvant 
ICIs. Research will also explore biomarkers that predict treatment 
response and those that might pre-empt the onset of significant toxicity. 
It is likely that the research conducted on the TransRAMPART samples 
will lead to tangible benefits for patients. 
The full support of our UK and international collaborators is essential 
to meet our ambitious accrual target of 1750 participants in order to 
complete this important trial aimed at improving the adjuvant treatment 
of renal cell carcinoma. 
An up-to-date version of the RAMPART protocol can be found at htt 
ps://www.rampart-trial.org/. 
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